Global Stable Isotope Labelled Compounds Market: The use of technologies such as mass spectrometry (MS) or nuclear magnetic resonance (NMR) has further expanded the research.

The global stable isotope labelled compounds market size is projected to reach USD 360 million by 2027 from USD 277.6 million in 2020, at a CAGR of 3.8 % between 2020 and 2027. Stable isotope-labelled compounds have generated considerable interest among researchers engaged in metabolism-mediated toxicity studies. Their role has risen in significance in assessment of in vivo metabolism in a vast range of metabolic research. The use of technologies such as mass spectrometry (MS) or nuclear magnetic resonance (NMR) has further expanded the research. These technologies have enabled researchers make better utilization of stable isotope labelled compounds for evaluating drugs’ disposition and their toxicity profile before they are used on patient populations. Their role has been rising in mechanistic toxicity studies as stable isotope-labelled compounds serve as a useful tool to enrich drug delivery research world over. Thus, they play a pivotal role in the management of several diseases, notably cancer and diabetes. Common stable isotope labelled compounds are 2H (Deuterium or D), 13C, 15N and 18O. Apart from metabolomics studies, stable isotope-labelled compounds are being increasingly used in environmental analysis, proteomics, and medical diagnostic research.

The report offers takes a critical and closer look at the current outlook and sheds light on emerging frontiers. The study findings are likely to form a useful guide for investors to identify lucrative avenues. The analyses of various growth dynamics in the stable isotope labelled compounds market helps emerging and established players to find out potential sources of revenue.

Rising body of research on the pharmaceutical and biotechnology industries is a key factor underpinning the rapid evolution of the stable isotope-labelled compounds market. In developed countries, investments in proteomics research have risen in recent years. Growing prevalence of various cancer types in several parts of the world is a key factor bolstering the demand for stable isotope-labelled compounds. Moreover, various drug toxicity studies have risen in volumes with the aim of developing effective therapeutics and diagnostics. Numerous emerging markets have been attractive sizeable investments in pharmaceutical research and development. Moreover, the high cost of stable isotope-labelled compounds may be a deterrent factor crippling the market prospects. Moreover, there is paucity of technical expertise for conducting pharmaceutical and biomedical research using stable isotope-labelled compounds.

Stable isotope-labelled compounds hold a large, promising potential in dynamic assessment of vivo metabolism in the paediatric population. Rising focus on accelerating the validation of new treatment modalities in order to reduce morbidity and mortality in pediatric populations is a key trend boosting the market.

The prominent players in the stable isotope labelled compounds market include PerkinElmer Inc. (US), Merck KGaA (Germany), Cambridge Isotope Laboratories, Inc. (US), URENCO Limited (UK), IsoSciences, LLC (US), Medical Isotopes, Inc. (US), Omicron Biochemicals, Inc. (US), Trace Sciences International (US), Alsachim (France), Taiyo Nippon Sanso Corporation (Japan), and Rotem Industries Israel Ltd. (Israel). Major players have focused on acquisitions, product launches, agreements, and partnerships to increase their shares in the global market.

North America is expected to dominate the stable isotope labelled compounds market. The major factors driving the growth of this market include the growth of the pharmaceutical and biopharmaceutical industry, the large nuclear industry in the US, the growth of the Canadian pharmaceutical industry, and the availability of funding in North American countries. North America is also expected to register the highest CAGR during the forecast period.